Pratikkumar Vekaria

Dr. Pratikkumar Vekaria

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2022 in Cureus
Verified
Journal Article
Open access
AVAnish Kizhakkekkara Vadukoot
Anish Kizhakkekkara Vadukoot
SMShabna Mottemmal
Shabna Mottemmal
PVPratikkumar Vekaria
Pratikkumar Vekaria
Cancer is a devastating disease condition and is the second most common etiology of death globally. After decades of research in the field of hematological malignancies and cellular therapeutics, we are still looking for therapeutic agents with the most efficacies and least toxicities. Curcumin is one of the cancer therapeutic agents that is derived from the Curcuma longa (turmeric) plant, and still in vitro and in vivo research is going on to find its beneficial effects on various cancers. Due to its potency to affect multiple targets of different cellular pathways, it is considered a promising agent to tackle various cancers alone or in combination with the existing chemotherapies. This review covers basic properties, mechanism of action, potential targets (molecules and cell-signaling pathways) of curcumin, as well as its effect on various solid and hematological malignancies.

28 April 2023 in Cureus
Verified
Journal Article
Open access
PDF file
HJHamna Javed
Hamna Javed
GJGowthami Sai Kogilathota Jagirdhar
Gowthami Sai Kogilathota Jagirdhar
RKRahul Kashyap
Rahul Kashyap
PVPratikkumar Vekaria
Pratikkumar Vekaria
MKMbbs Rahul Kashyap
Mbbs Rahul Kashyap
Liraglutide is an anti-diabetic medication used for the treatment of type 2 diabetes mellitus, obesity, and chronic weight management. It is a glucagon-like peptide-1 (GLP-1) agonist that helps reduce postprandial hyperglycemia for up to 24 h after administration. It stimulates endogenous insulin secretion according to glucose levels, and also delays gastric emptying and suppresses prandial glucagon secretion. Some of the common complications associated with liraglutide include hypoglycemia, headache, diarrhea, nausea, and vomiting. Uncommon adverse effects include pancreatitis, kidney failure, pancreatic cancer, and injection site reactions. In this article, we discussed a case of a 73-year-old male with a history of uncontrolled type 2 diabetes mellitus on long-term insulin and liraglutide who presented with abdominal pain, subjective fevers, dry heaves, tachycardia, and mildly reduced oxygen saturation. The patient was diagnosed with pancreatitis on the basis of laboratory and imaging findings. Liraglutide was discontinued, and the patient received supportive care with significant clinical improvement. The use of GLP-1 inhibitors has been increasing not only for diabetes mellitus management, but also for its promising effect on weight management. The literature review endorses our case report findings, and also discusses other complications of liraglutide. Therefore, we recommend to be cognizant of these side-effects upon starting liraglutide.

7 November 2022 in Frontiers in Medicine
Verified
Journal Article
Open access
PVPratikkumar Vekaria
Pratikkumar Vekaria
ASAreej Syed
Areej Syed
JAJeffrey Anderson
Jeffrey Anderson
BCBrendon Cornett
Brendon Cornett
ABAmine Bourbia
Amine Bourbia
ASAsif R. Shah
Asif R. Shah
Background: We conducted a retrospective cohort study on COVID-19 patients with and without dementia by extracting data from the HCA Healthcare Enterprise Data Warehouse between January-September 2020.Aims: To describe the role of patients' baseline characteristics specifically dementia in determining overall health outcomes in COVID-19 patients.Methods: We grouped in-patients who had ICD-10 codes for dementia (DM) with age and gender-matched (1:2) patients without dementia (ND). Our primary outcome variables were in-hospital mortality, length of stay, Intensive Care Unit (ICU) admission, ICU-free days, mechanical ventilation (MV) use, MV-free days and 90-day re-admission.Results: Matching provided similar age and sex in DM and ND groups. BMI (median, 25.8 vs. 27.6) and proportion of patients who had smoked (23.3 vs. 31.3%) were lower in DM than in ND patients. The median (IQR) Elixhauser Comorbidity Index was higher in dementia patients 7 (5–10) vs. 5 (3–7, p < 0.01). Higher mortality was observed in DM group (30.8%) vs. ND group (26.4%, p < 0.01) as an unadjusted univariate analysis. The 90-day readmission was not different (32.1 vs. 31.8%, p = 0.8). In logistic regression analysis, the odds of dying were not different between patients in DM and ND groups (OR = 1.0; 95% CI 0.86–1.17), but the odds of ICU admissions were significantly lower for dementia patients (OR = 0.58, 95% CI 0.51–0.66).Conclusions: Our data showed that COVID-19 patients with dementia did not fare substantially worse, but in fact, fared better when certain metrics were considered.

11 October 2022 in Qeios Preprints
Verified
Preprint
Open access
PDF file
PVPratikkumar Vekaria
Pratikkumar Vekaria
ASAreej Syed
Areej Syed
JAJeffrey Anderson
Jeffrey Anderson
BCBrendon Cornett
Brendon Cornett
ABAmine Bourbia
Amine Bourbia
ASAsif R Shah
Asif R Shah
BACKGROUND We conducted a retrospective cohort study on COVID-19 patients with and without dementia by extracting data from the HCA Healthcare Enterprise Data Warehouse between January-September 2020. AIMS To describe the role of patients' baseline characteristics specifically dementia in determining overall health outcomes in COVID-19 patients. METHODS We grouped in-patients who had ICD-10 codes for dementia (DM) with age and gender-matched (1:2) patients without dementia (ND). Our primary outcome variables were in-hospital mortality, length of stay, Intensive Care Unit (ICU) admission, ICU-free days, mechanical ventilation (MV) use, MV-free days and 90-day re-admission. RESULTS Matching provided similar age and sex in DM and ND groups. BMI (median, 25.8 vs. 27.6) and proportion of patients who had smoked (23.3% vs. 31.3%) were lower in DM than in ND patients. The median (IQR) Elixhauser Comorbidity Index was higher in dementia patients 7 (5-10) vs. 5 (3-7, p < 0.01). Higher mortality was observed in DM group (30.8%) vs. ND group (26.4%, p < 0.01) as an unadjusted univariate analysis. The 90-day readmission was not different (32.1% vs. 31.8%, p=0.8). In logistic regression analysis, the odds of dying were not different between patients in DM and ND groups (OR=1.0; 95% CI 0.86-1.17), but the odds of ICU admissions were significantly lower for dementia patients (OR=0.58, 95% CI 0.51-0.66). CONCLUSIONS Our data showed that COVID-19 patients with dementia did not fare substantially worse, but in fact, fared better when certain metrics were considered.

29 May 2025 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Closed access
PDF file
UTUmabalan Thirupathy
Umabalan Thirupathy
SKSrujana Konka
Srujana Konka
JSJohnnie Saifa-Bonsu
Johnnie Saifa-Bonsu
NHNagaraj Sanchitha Honganur
Nagaraj Sanchitha Honganur
MDMihir Dave
Mihir Dave
PVPratikkumar Vekaria
Pratikkumar Vekaria